GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Personal Services » Medifast Inc (NYSE:MED) » Definitions » ROE %

Medifast (Medifast) ROE % : 12.24% (As of Dec. 2023)


View and export this data going back to 1981. Start your Free Trial

What is Medifast ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Medifast's annualized net income for the quarter that ended in Dec. 2023 was $24 Mil. Medifast's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $197 Mil. Therefore, Medifast's annualized ROE % for the quarter that ended in Dec. 2023 was 12.24%.

The historical rank and industry rank for Medifast's ROE % or its related term are showing as below:

MED' s ROE % Range Over the Past 10 Years
Min: 14.74   Med: 53.52   Max: 91.2
Current: 54.86

During the past 13 years, Medifast's highest ROE % was 91.20%. The lowest was 14.74%. And the median was 53.52%.

MED's ROE % is ranked better than
92.78% of 97 companies
in the Personal Services industry
Industry Median: 8.56 vs MED: 54.86

Medifast ROE % Historical Data

The historical data trend for Medifast's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medifast ROE % Chart

Medifast Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.84 78.49 91.20 80.31 55.77

Medifast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.43 98.10 67.96 48.88 12.24

Competitive Comparison of Medifast's ROE %

For the Personal Services subindustry, Medifast's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medifast's ROE % Distribution in the Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, Medifast's ROE % distribution charts can be found below:

* The bar in red indicates where Medifast's ROE % falls into.



Medifast ROE % Calculation

Medifast's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=99.415/( (155.044+201.481)/ 2 )
=99.415/178.2625
=55.77 %

Medifast's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=24.14/( (193.035+201.481)/ 2 )
=24.14/197.258
=12.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Medifast  (NYSE:MED) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=24.14/197.258
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(24.14 / 764.06)*(764.06 / 314.9635)*(314.9635 / 197.258)
=Net Margin %*Asset Turnover*Equity Multiplier
=3.16 %*2.4259*1.5967
=ROA %*Equity Multiplier
=7.67 %*1.5967
=12.24 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=24.14/197.258
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (24.14 / 39.208) * (39.208 / 34.704) * (34.704 / 764.06) * (764.06 / 314.9635) * (314.9635 / 197.258)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6157 * 1.1298 * 4.54 % * 2.4259 * 1.5967
=12.24 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Medifast ROE % Related Terms

Thank you for viewing the detailed overview of Medifast's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medifast (Medifast) Business Description

Traded in Other Exchanges
Address
100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
Executives
Jeffrey J Brown director 19900 MACARTHUR BLVD, SUITE 570, IRVINE CA 92612
Andrea B Thomas director C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Michael A. Hoer director MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Scott Schlackman director 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Hallquist Constance J. director 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Elizabeth A. Geary director C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Daniel R Chard director, officer: Chief Executive Officer NU SKIN ENTERPRISES, INC., 75 WEST CENTER STREET, PROVO UT 84601
Jonathan Barrett Mackenzie officer: VP, Finance & CAO 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Kevin G Byrnes director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Michael C Macdonald director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
James P. Maloney officer: Chief Financial Officer 415 HOLIDAY DRIVE, PITTSBURGH PA 15220
Ming Xian director MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Carl E Sassano director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Joseph P Kelleman officer: (Interim) CFO 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Timothy G Robinson officer: Chief Financial Officer C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117

Medifast (Medifast) Headlines